Trevi Therapeutics, Inc. (TRVI): Shareholders' Equity
$183.24M
As of 2025-12-31
$321.51M
As of 2026-06-30
+19.5%
3-year compound annual growth
+46.4%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $183.24M | +83.9% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $99.64M | +20.7% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $82.55M | -23.2% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $107.46M | +529.3% | 2024-03-20, Balance as of period end |
| 2021-12-31 | $17.07M | -37.4% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $27.28M | -50.0% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $54.55M | n/m | 2021-03-25, Balance as of period end |
| 2018-12-31 | -$109.49M | n/a | 2020-03-16, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $183.24M | +83.9% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $159.21M | -14.7% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | -$108.50M | n/m |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$105.47M | n/m |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $49.87M | +119.3% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $107.54M | -26.3% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $151.14M | -0.2% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $177.01M | +81.9% |
| COMPASS Pathways plc (CMPS) | 2025-12-31 | -$52.85M | n/m |
Compare TRVI, ACET, FHTX, URGN side by side · Screen every company in Pharmaceutical Preparations ↗